Phase Ib gene editing trials market advancing with novel in vivo CRISPR therapies like Verve 101, NTLA 2001 and PBGENE HBV in early testing. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Phase Ib Gene Editing Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Phase Ib Gene Editing Trials Market, by Gene Editing Platform
8.1.1. CRISPR/Cas Systems (e.g., Cas9, Cas12, Cas13)
8.1.1.1. Market Revenue and Forecast
8.1.2. Zinc Finger Nucleases (ZFNs)
8.1.2.1. Market Revenue and Forecast
8.1.3. TALENs (Transcription Activator-Like Effector Nucleases)
8.1.3.1. Market Revenue and Forecast
8.1.4. Meganucleases
8.1.4.1. Market Revenue and Forecast
8.1.5. Base & Prime Editors
8.1.5.1. Market Revenue and Forecast
9.1. Phase Ib Gene Editing Trials Market, by Therapy Type
9.1.1. In Vivo Gene Editing Therapies
9.1.1.1. Market Revenue and Forecast
9.1.2. Ex Vivo Gene Editing Therapies
9.1.2.1. Market Revenue and Forecast
10.1. Phase Ib Gene Editing Trials Market, by Disease Area
10.1.1. Oncology (e.g., gene-edited T-cell therapies)
10.1.1.1. Market Revenue and Forecast
10.1.2. Rare Genetic Disorders
10.1.2.1. Market Revenue and Forecast
10.1.3. Hematological Disorders (e.g., sickle cell, beta-thalassemia)
10.1.3.1. Market Revenue and Forecast
10.1.4. Ophthalmology
10.1.4.1. Market Revenue and Forecast
10.1.5. Infectious Diseases
10.1.5.1. Market Revenue and Forecast
10.1.6. Neurology
10.1.6.1. Market Revenue and Forecast
10.1.7. Cardiovascular Disorders
10.1.7.1. Market Revenue and Forecast
11.1. Phase Ib Gene Editing Trials Market, by Delivery Method
11.1.1. Lipid Nanoparticles (LNPs)
11.1.1.1. Market Revenue and Forecast
11.1.2. Electroporation
11.1.2.1. Market Revenue and Forecast
11.1.3. Viral Vectors
11.1.3.1. Market Revenue and Forecast
11.1.4. Non-Viral Vectors
11.1.4.1. Market Revenue and Forecast
12.1. Phase Ib Gene Editing Trials Market, by Trial Sponsor Type
12.1.1. Biotech/Pharma Companies
12.1.1.1. Market Revenue and Forecast
12.1.2. Academic Institutions
12.1.2.1. Market Revenue and Forecast
12.1.3. Non-Profit Research Organizations
12.1.3.1. Market Revenue and Forecast
12.1.4. Public-Private Collaborations
12.1.4.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Gene Editing Platform
13.1.2. Market Revenue and Forecast, by Therapy Type
13.1.3. Market Revenue and Forecast, by Disease Area
13.1.4. Market Revenue and Forecast, by Delivery Method
13.1.5. Market Revenue and Forecast, by Trial Sponsor Type
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Gene Editing Platform
13.1.6.2. Market Revenue and Forecast, by Therapy Type
13.1.6.3. Market Revenue and Forecast, by Disease Area
13.1.6.4. Market Revenue and Forecast, by Delivery Method
13.1.6.5. Market Revenue and Forecast, by Trial Sponsor Type
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Gene Editing Platform
13.1.7.2. Market Revenue and Forecast, by Therapy Type
13.1.7.3. Market Revenue and Forecast, by Disease Area
13.1.7.4. Market Revenue and Forecast, by Delivery Method
13.1.7.5. Market Revenue and Forecast, by Trial Sponsor Type
13.2. Europe
13.2.1. Market Revenue and Forecast, by Gene Editing Platform
13.2.2. Market Revenue and Forecast, by Therapy Type
13.2.3. Market Revenue and Forecast, by Disease Area
13.2.4. Market Revenue and Forecast, by Delivery Method
13.2.5. Market Revenue and Forecast, by Trial Sponsor Type
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Gene Editing Platform
13.2.6.2. Market Revenue and Forecast, by Therapy Type
13.2.6.3. Market Revenue and Forecast, by Disease Area
13.2.7. Market Revenue and Forecast, by Delivery Method
13.2.8. Market Revenue and Forecast, by Trial Sponsor Type
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Gene Editing Platform
13.2.9.2. Market Revenue and Forecast, by Therapy Type
13.2.9.3. Market Revenue and Forecast, by Disease Area
13.2.10. Market Revenue and Forecast, by Delivery Method
13.2.11. Market Revenue and Forecast, by Trial Sponsor Type
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Gene Editing Platform
13.2.12.2. Market Revenue and Forecast, by Therapy Type
13.2.12.3. Market Revenue and Forecast, by Disease Area
13.2.12.4. Market Revenue and Forecast, by Delivery Method
13.2.13. Market Revenue and Forecast, by Trial Sponsor Type
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Gene Editing Platform
13.2.14.2. Market Revenue and Forecast, by Therapy Type
13.2.14.3. Market Revenue and Forecast, by Disease Area
13.2.14.4. Market Revenue and Forecast, by Delivery Method
13.2.15. Market Revenue and Forecast, by Trial Sponsor Type
13.3. APAC
13.3.1. Market Revenue and Forecast, by Gene Editing Platform
13.3.2. Market Revenue and Forecast, by Therapy Type
13.3.3. Market Revenue and Forecast, by Disease Area
13.3.4. Market Revenue and Forecast, by Delivery Method
13.3.5. Market Revenue and Forecast, by Trial Sponsor Type
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Gene Editing Platform
13.3.6.2. Market Revenue and Forecast, by Therapy Type
13.3.6.3. Market Revenue and Forecast, by Disease Area
13.3.6.4. Market Revenue and Forecast, by Delivery Method
13.3.7. Market Revenue and Forecast, by Trial Sponsor Type
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Gene Editing Platform
13.3.8.2. Market Revenue and Forecast, by Therapy Type
13.3.8.3. Market Revenue and Forecast, by Disease Area
13.3.8.4. Market Revenue and Forecast, by Delivery Method
13.3.9. Market Revenue and Forecast, by Trial Sponsor Type
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Gene Editing Platform
13.3.10.2. Market Revenue and Forecast, by Therapy Type
13.3.10.3. Market Revenue and Forecast, by Disease Area
13.3.10.4. Market Revenue and Forecast, by Delivery Method
13.3.10.5. Market Revenue and Forecast, by Trial Sponsor Type
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Gene Editing Platform
13.3.11.2. Market Revenue and Forecast, by Therapy Type
13.3.11.3. Market Revenue and Forecast, by Disease Area
13.3.11.4. Market Revenue and Forecast, by Delivery Method
13.3.11.5. Market Revenue and Forecast, by Trial Sponsor Type
13.4. MEA
13.4.1. Market Revenue and Forecast, by Gene Editing Platform
13.4.2. Market Revenue and Forecast, by Therapy Type
13.4.3. Market Revenue and Forecast, by Disease Area
13.4.4. Market Revenue and Forecast, by Delivery Method
13.4.5. Market Revenue and Forecast, by Trial Sponsor Type
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Gene Editing Platform
13.4.6.2. Market Revenue and Forecast, by Therapy Type
13.4.6.3. Market Revenue and Forecast, by Disease Area
13.4.6.4. Market Revenue and Forecast, by Delivery Method
13.4.7. Market Revenue and Forecast, by Trial Sponsor Type
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Gene Editing Platform
13.4.8.2. Market Revenue and Forecast, by Therapy Type
13.4.8.3. Market Revenue and Forecast, by Disease Area
13.4.8.4. Market Revenue and Forecast, by Delivery Method
13.4.9. Market Revenue and Forecast, by Trial Sponsor Type
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Gene Editing Platform
13.4.10.2. Market Revenue and Forecast, by Therapy Type
13.4.10.3. Market Revenue and Forecast, by Disease Area
13.4.10.4. Market Revenue and Forecast, by Delivery Method
13.4.10.5. Market Revenue and Forecast, by Trial Sponsor Type
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Gene Editing Platform
13.4.11.2. Market Revenue and Forecast, by Therapy Type
13.4.11.3. Market Revenue and Forecast, by Disease Area
13.4.11.4. Market Revenue and Forecast, by Delivery Method
13.4.11.5. Market Revenue and Forecast, by Trial Sponsor Type
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Gene Editing Platform
13.5.2. Market Revenue and Forecast, by Therapy Type
13.5.3. Market Revenue and Forecast, by Disease Area
13.5.4. Market Revenue and Forecast, by Delivery Method
13.5.5. Market Revenue and Forecast, by Trial Sponsor Type
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Gene Editing Platform
13.5.6.2. Market Revenue and Forecast, by Therapy Type
13.5.6.3. Market Revenue and Forecast, by Disease Area
13.5.6.4. Market Revenue and Forecast, by Delivery Method
13.5.7. Market Revenue and Forecast, by Trial Sponsor Type
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Gene Editing Platform
13.5.8.2. Market Revenue and Forecast, by Therapy Type
13.5.8.3. Market Revenue and Forecast, by Disease Area
13.5.8.4. Market Revenue and Forecast, by Delivery Method
13.5.8.5. Market Revenue and Forecast, by Trial Sponsor Type
14.1. Caribou Biosciences
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Cellectis
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Intellia Therapeutics
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. LogicBio Therapeutics
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Poseida Therapeutics
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Precision BioSciences
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Regenxbio
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Sana Biotechnology
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Sangamo Therapeutics
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Tessera Therapeutics
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description